Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.41 -0.45 (-1.66%)

Streaming Delayed Price Updated: 12:05 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Via The Motley Fool

Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology

February 11, 2026

Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...

Via Finterra

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Via The Motley Fool

Is 2026 the Year of Dividend Stocks? These 2 Income-Focused ETFs Have Been Soaring Past the S&P 500 ↗

February 10, 2026

These funds both pay more than 3% and have been beating the market this year.

Via The Motley Fool

Topics ETFs Stocks

CVS Health Navigates a Stormy 2026: Record Revenue Tempered by Medicare Advantage Costs and PBM Turmoil

February 10, 2026

In a pivotal earnings report delivered on February 10, 2026, CVS Health (NYSE: CVS) showcased a complex narrative of financial resilience and operational headwinds. While the healthcare giant posted...

Via MarketMinute

Topics Economy

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

February 10, 2026

Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...

Via Finterra

Topics Artificial Intelligence Economy Fraud

Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse

February 10, 2026

February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a...

Via Finterra

Topics Economy World Trade

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Via The Motley Fool

5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call

February 10, 2026

Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins....

Via StockStory

Topics Artificial Intelligence Earnings

Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend? ↗

February 09, 2026

The stock has been fairly stable over the past year.

Via The Motley Fool

Topics Intellectual Property

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

February 06, 2026

Which of the highest-yielding healthcare stocks are value traps or golden opportunities?

Via The Motley Fool

AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology

February 06, 2026

In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a...

Via TokenRing AI

Topics Artificial Intelligence

Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal

February 06, 2026

In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially....

Via MarketMinute

Topics Economy Government Immigration

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

Via Finterra

Topics Economy Government Intellectual Property

Broad-Based Prosperity: S&P 500 Defies Headwinds with 10.1% Growth as Tech Reclaims Its Crown

February 06, 2026

The fourth-quarter earnings season of 2025 has reached a fever pitch, delivering a resounding message of resilience to Wall Street. As of February 6, 2026, the S&P 500 has reported an aggregate...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

February 06, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

February 05, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗

February 05, 2026

Via MarketBeat

Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain

February 05, 2026

The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Pfizer (PFE) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q4 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Pfizer (PFE) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Pfizer (PFE) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Pfizer (PFE) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Men's Health Network Launches "My Cancer, My Plan" Podcast on World Cancer Day

February 05, 2026

Via PRLog

Topics Death

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

February 05, 2026

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Via Finterra

Topics Earnings Economy Intellectual Property

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗

February 05, 2026

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Via The Motley Fool

These S&P500 stocks are the most active in today's session ↗

February 04, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.